Interféron-lambda human, ;, recombinant, exprimé en E. coli, > = 98 % (SDS - PAGE), >= 98%( HPLC) , testé sur la culture CELLULAIRE

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Interleukin-29 (IL-29) enhances the production of interleukins from monocytes. It has been observed that it stimulates antiviral responses to herpes simplex virus 1 in vitro. Serums from patients with rheumatoid arthritis have high levels of IL29.

General description

IFN-λ-1,-2, and -3 (also known as IL-29, IL-28A and IL-28B respectively) are distantly related to the IL-10 family of interferons. All three IFN-λs use a distinct receptor system composed of an IFN-λR1 subunit (also called CRF2-12) and IL-10R2 subunit (also called CRF2-14). Signaling through this receptor system induces antiviral defense similar but distinct than the type I Interferons. Recombinant human IFN-L1 is a 19.8kDa protein containing 178 amino acid residues.

Physical form

Lyophilized from 1x PBS.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.5-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Sequence

PTSKPTTTGK GCHIGRFKSL SPQELASFKK ARDALEESLK LKNWSCSSPV FPGNWDLRLL QVRERPVALE AELALTLKVL EAAAGPALED VLDQPLHTLH HILSQLQACI QPQPTAGPRP RGRLHHWLHR LQEAPKKESA GCLEASVTFN LFRLLTRDLK YVADGNLCLR TSTHPEST